Generic Name and Formulations:
Butenafine HCl 1%; crm.
Indications for MENTAX:
Tinea versicolor, t. corporis, t. cruris, and interdigital t. pedis.
Apply to affected and immediately surrounding area. T. versicolor, corporis, cruris: Apply once daily for 2 wks. T. pedis: Apply twice daily for 1 wk, or once daily for 4 wks. Reevaluate if no improvement after therapy.
Avoid eyes, nose, mouth, mucous membranes. Do not occlude. Discontinue if irritation develops and confirm diagnosis. Sensitivity to allylamines. Pregnancy (Cat.B). Nursing mothers.
Burning/stinging, worsening of condition, other local irritation.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force